Amresh Kumar Singh¹*, Nandini Singh², Sushil Kumar³ and Ankur Kumar⁴

¹Assistant Professor, Head/Incharge CiOVID-19 Laboratory, Department of Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India

*Corresponding Author: Amresh Kumar Singh, Assistant Professor, Head/Incharge CiOVID-19 Laboratory, Department of Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India.

Received: March 16, 2022; Published: April 26, 2022

Abstract

MRSA (methicillin-resistant Staphylococcus aureus) is a prevalent cause of infection in hospitals and at community level. It causes bacteraemia, pneumonia, endocarditis, skin and soft tissue infections and bone and joint infections. Although its prevalence has started declining before the pandemic of COVID-19, but extensive use of antibiotics and long-term hospitalization during infection have increases the risk of secondary bacterial infection including MRSA. As a result, occurrences of co-infection and super-infection are on the rise. MRSA is responsible for collateral damage among patients with COVID-19 infection. In this review, recently published comprehensive studies have assessed the MRSA co-infection among hospitalised COVID-19 patients through PubMed, Scopus, Google Scholar, and the WHO COVID-19 databases. According to recent studies, it was found that MRSA co-infections are on the rise among COVID-19 patients which has increased the mortality rate. Improved diagnostic capabilities of laboratories and reducing the necessity of antibiotic that can be helpful in reducing the MRSA co-infection in these patients. Sanitation and preventive measures and strict infection control policies can reduce the burden of MRSA infection.

Keywords: Staphylococcus aureus; COVID-19; MRSA

References

1. Antimicrobial resistance, WHO factsheet.
2. Siddiqui AH and Koirala J. “Methicillin Resistant Staphylococcus aureus”. In: StatPearls. Treasure Island (FL): StatPearls Publishing; (2021).
3. Kluytmans-Vandenbergh MF and Kluytmans JA. “Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives”. Clinical Microbiology and Infection1 (2006): 9-15.
4. Buck JM., et al. “Community-associated Methicillin-resistant Staphylococcus aureus Minnesota, 2000-2003”. Emerging Infectious Diseases 11 (2005): 1532-1538.
5. Lakhundi S and Zhang K. “Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology”. Clinical Microbiology Review4 (2018): e00020-18.
6. Dandagi GL. “Nosocomial pneumonia in critically ill patients”. Lung India3 (2010): 149-153.
7. Rawson TM., et al. “COVID-19 and the potential long-term impact on antimicrobial resistance”. Journal of Antimicrobial Chemotherapy7 (2020): 1681-1684.
8. Tong SY., et al. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management”. Clinical Microbiology Reviews 3 (2015): 603-661.
9. DeLeo FR., et al. “Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus”. Proceedings of the National Academy of Sciences of the United States of America 44 (2011): 18091-18096.
10. Alvarez-Uria G and Reddy R. “Prevalence and Antibiotic Susceptibility of Community-Associated Methicillin-Resistant Staphylococcus aureus in a Rural Area of India: Is MRSA Replacing Methicillin-Susceptible Staphylococcus aureus in the Community?”. ISRN Dermatology 2012 (2012): 248951.
11. Murchan S., et al. “Emergence, spread, and characterization of phage variants of epidemic methicillin-resistant Staphylococcus aureus 16 in England and Wales”. Journal of Clinical Microbiology 11 (2004): 5154-5160.
12. Song JH., et al. “Spread of methicillin-resistant Staphylococcus aureusbetween the community and the hospitals in Asian countries: an ANSORP study”. Journal of Antimicrobial Chemotherapy 66 (2011): 1061-1069.
13. Kourtis AP., et al. “Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States”. MMWR Morbidity and Mortality Weekly Report 9 (2019): 214-219.
14. Turner NA., et al. “Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research”. Nature Reviews Microbiology 4 (2019): 203-218.
15. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India. “Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence and susceptibility pattern”. Indian Journal of Medical Research 2 (2013): 363-369.
16. Hiramatsu K., et al. “Genomic Basis for Methicillin Resistance in Staphylococcus aureus”. Infectious Chemotherapy 2 (2013): 117-136.
17. Steinig EJ., et al. “Evolution and Global Transmission of a Multidrug-Resistant, Community-Associated Methicillin-Resistant Staphylococcus aureus Lineage from the Indian Subcontinent”. mBio6 (2019): e01105-1119.
18. D'Souza N., et al. “Molecular characterization of methicillin-resistant Staphylococcus aureus with emergence of epidemic clones of sequence type (ST) 22 and ST)772 in Mumbai, India”. Journal of Clinical Microbiology5 (2010): 1806-18011.
19. Sunagar R., et al. “Prevalence and genotype distribution of methicillin-resistant Staphylococcus aureus (MRSA) in India”. Journal of Global Antimicrobial Resistance 7 (2016): 46-52.
20. van Duijkeren E., et al. “Methicillin-resistant Staphylococcus aureus in pigs with exudative epidermitis”. Emerging Infectious Diseases 9 (2007): 1408-14010.
21. Hassoun A., et al. “Incidence, prevalence, and management of MRSA bacteraemia across patient populations-a review of recent developments in MRSA management and treatment”. Critical Care1 (2017): 211.
22. Ramakrishnan K., et al. “Skin and Soft Tissue Infections”. American Family Physician6 (2015): 474-483.
23. Stryjewski ME and Chambers HF. “Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus”. Clinical Infectious Disease5 (2008): S368-377.
24. Prabhoo R., et al. “Overview of methicillin resistant Staphylococcus aureus mediated bone and joint infections in India”. Orthopaedic Review (Pavia)2 (2019): 8070.
25. Darley ES and MacGowan AP. “Antibiotic treatment of gram-positive bone and joint infections”. Journal of Antimicrobe Chemotherapy 6 (2004): 928-935.
26. Jean SS., et al. “Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia”. Journal of Clinical Medicine1 (2020): 275.
27. Shetty K., et al. “Hospital-Acquired Pneumonia (Nosocomial Pneumonia) and Ventilator-Associated Pneumonia”. Drugs and Diseases Infectious Diseases Medscape (2021).
28. Cunha BA. "Methicillin‐resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy". Clinical Microbiology and Infection11 (2005): 33-42.
29. Zumo AL and Greenberg A. “Staphylococcal Meningitis”. Drugs and Diseases > Neurology Medscape (2018).
30. European Centre for Disease Prevention and Control. “Summary of the latest data on antibiotic resistance in the European Union” (2017).
31. Lohan K., et al. “Prevalence pattern of MRSA from a rural medical college of North India: A cause of concern”. Journal of Family Medicine and Primary Care 2 (2021): 752-757.
32. Kourtis AP., et al. “Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections—United States”. MMWR Morbidity and Mortality Weekly Report 68 (2019): 214-219.
33. Bes TM., et al. “Prevalence of methicillin-resistant Staphylococcus aureus colonization in individuals from the community in the city of Sao Paulo, Brazil”. Rev Inst Med Trop Sao Paulo 60 (2018): e58.
34. Facciolà A., et al. “MRSA detection in South Italy an epidemiological survey to evaluate the burden of this important public health issue”. Infectious Diseases and Tropical Medicine 3 (2018): e486.
35. Al Jalaf M., et al. “Methicillin resistant Staphylococcus aureus in emergency department patients in the United Arab Emirates”. BMC Emergency Medicine 18 (2018): 12.
36. Kumar A., et al. “Prevalence of Methicillin Resistant Staphylococcus aureus in Tertiary Care Teaching Hospital, Western India”. International Conference of Advance Research and Innovation (ICARI) (2015).
37. Weiner-Lastinger LM., et al. “The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network”. Infection Control and Hospital Epidemiology 1 (2022): 12-25.
38. Saini V., et al. “Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19 Pandemic”. Antibiotics (Basel)8 (2021): 954.
39. Polly M., et al. “Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil”. American Journal of Infection Control1 (2022): 32-38.
40. Pasquini Z., et al. “Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study”. International Journal of Infectious Diseases 111 (2021): 31-36.
41. Lai C-C., et al. “High burden of antimicrobial drug resistance in Asia”. Journal of Global Antimicrobial Resistance 3 (2014): 141-147.
42. Senok A., et al. “Coinfections in Patients Hospitalized with COVID-19: A Descriptive Study from the United Arab Emirates”. Infection and Drug Resistance 14 (2021): 2289-2296.
43. Punjabi CD., et al. “Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia”. Infection Control and Hospital Epidemiology 9 (2021): 1156-1158.
44. Bhargava A., et al. “High rate of Multidrug-Resistant Organisms (MDROs) among COVID-19 patients presenting with bacteraemia upon hospital admission”. American Journal of Infection Control 11 (2021): 1441-1442.
45. Raychaudhuri D., et al. “COVID-19 and Co-infection in Children: The Indian Perspectives”. Journal of Tropical Pediatrics 4 (2021): fmab073.
46. Wolfe A., et al. “Co-occurrence of SARS-CoV-2 and respiratory pathogens in the frail elderly”. (2020).
47. Garcia-Vidal C., et al. “Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study”. Clinical Microbiology and Infection 1 (2021): 83-88.
48. Diao B., et al. “Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)”. Frontiers in Immunology 11 (2020): 1-7.
49. Bengoechea JA. and Bamford CG. “SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?” EMBO Molecular Medicine7 (2020): e12560.
50. Klein NC., et al. “Infections associated with steroid use”. Infectious Disease Clinics of North America2 (2001): 423-432.
51. McCraw C., et al. “Community-Acquired, Post-COVID-19, Methicillin-Resistant Staphylococcus aureus Pneumonia and Empyema”. Cureus 2 ( 2022): e22121.
52. Kanungo R. “Antimicrobial resistance and the COVID -19 pandemic: A double threat”. Indian Journal of Medical Microbiology 4 (2021): 401.

Citation

Citation: Amresh Kumar Singh., et al. “Role and Impact of Methicillin-resistant Staphylococcus aureus: A New Paradigm in Antibiotic Era During COVID- 19 Pandemic". Acta Scientific Microbiology 5.5 (2022): 90-100.

Copyright

Copyright: © 2022 Amresh Kumar Singh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.